Oxford Biomedica Plc · LSE:OXB
Oxford Biomedica — H1 2018 Earnings Presentation
20 slides from Oxford Biomedica's earnings presentation, Sep 13, 2018
Slide 1: The LentiVector Platform Company
The LentiVector® Platform Company A leader in gene and cell therapy Interim results for six months ended 30 June 2018 13 September 2018
Slide 2: Forward-looking statements
Forward-looking statements This presentation does not constitute an offer to sell or a solicitation of offers to buy Ordinary Shares (the “Securities”). Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions 2 Cohort expressed
Slide 3: Operational and Financial Highlights
Operational and Financial Highlights
Slide 4: Operational highlights
Operational highlights Novartis’ commercialised product Kymriah® • Novartis collaboration progressing well, with Kymriah approved in the US to treat adults with r/r DLBCL and in the EU for children and young adults with r/r ALL and r/r DLBCL Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPD
Slide 5: Financial highlights
Financial highlights Revenue • Gross income growth of 118% to £36.0 million (H1 2017: £15.7 million) •Cohort Licence income 2 Dose of £18.3Administration million (Axovant and Bioverativ), 3 months (UPDRS) segmented 6 months (UPDRS) by Product 1 year (UPDRS) (£10.2 2 years (UPDRS) 1, n=3 million) and
Slide 6: Platform
x Oxford! Platform
Slide 7: Novartis CAR-T partnership progress
Novartis CAR-T partnership progress Novartis partnership in place since 2014, with new agreement in 2017 News release (05 Sept 2018) Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) Simon Stevens, Chief2 Executive 1 year (UPDRS) NHS years (UPDRS) England said: 1, n=3 1x Original Mean 27
Slide 8: Developing the LentiVector platform
Developing the LentiVector® platform Expansion of capacity to meet long-term demand (March 2018) • £20.5 million (gross) equity fundraise in March 2018 to fund the expansion • Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) Group leased a new facility in
Slide 9: Platform pipeline
Platform pipeline Product Indication Pre-Clinical Phase I Phase I/II Phase II Phase III Approval LentiVector® platform Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) Kymriah1 r/r ALL 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Max. up to 30% M
Slide 10: Extensive lentiviral vector clinical/pre-clinical trial activity
Extensive lentiviral vector clinical/pre-clinical trial activity Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Max. up to 30% Max. up to 50% Max. up to 44% Max. up to 30% 2, n=3 2x Original Mean 28%
Slide 11: Products
x Oxford! Products
Slide 12: Progress with proprietary product development
Progress with proprietary product development • During the period the group continued to prepare the priority programmes for clinical studies Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) • 1, n=3 $842 million1xexclusive worldwide Original agreement Mea
Slide 13: Product pipeline
Product pipeline Product Indication Pre-Clinical Phase I Phase I/II Phase II Phase III Approval Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) OXB Proprietary Products 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Corneal graft Max. up to 30% Ma
Slide 14: Financial Review
x Oxford! Financial Review
Slide 15: Gross income and EBIDA
Gross income1 and EBIDA2 Gross income (£m) Includes £18.3m Axovant and Bioverativ license fees 40 Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 30 1, n=3 1x Includes £6.1m Original Mean 27% Mean 30% Mean 29% Mean 20% Novartis license fees Max. up to 30%
Slide 16: Segmental analysis
Segmental analysis Platform segment (£m) Product segment (£m) H1 2016 H2 2016 H1 2017 H2 2017 H1 2018 H1 2016 H2 2016 H1 2017 H2 2017 H1 2018 Cohort2 30 Dose Administration 3 months (UPDRS) 12 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1,25 n=3 1x Original Mean 27%10 Mean 30% Mean 29% Mean 20%
Slide 17: Expected news flow
Expected news flow Partners’ programmes Novartis Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 2nd CAR-T Royalty stream from 1, n=3 1x Original 1 Regulatory Mean 27% submissions Mean 30% for paediatric Mean r/r29% ALL and adult Mean 20% r/r programme to
Slide 18: Outlook
Outlook • Demand for process development and manufacture of lentiviral vectors remains very strong - further contracts with new partner companies may be concluded over the next twelve months 2 Cohort Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Origi
Slide 19: A world leading gene and cell therapy company
A world leading gene and cell therapy company Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Max. up to 30% Max. up to 50% Max. up to 44% Max. up to 30% 2, n=3 2x Original Mean 28% Mean 34% Mean 29%
Slide 20: Contact Us
Contact Us Oxford BioMedica plc Windrush Court Transport Way Oxford OX4 6LT John Dawson, CEO Stuart Paynter, CFO Tel: +44 (0) 1865 783 000 enquiries@oxfordbiomedica.co.uk www.oxfordbiomedica.co.uk